Cover Image
市場調查報告書

品牌學名吸入藥的盈利評估

Profitability Assessment of Branded Generic Inhalers

出版商 Datamonitor Healthcare 商品編碼 342052
出版日期 內容資訊 英文 48 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
品牌學名吸入藥的盈利評估 Profitability Assessment of Branded Generic Inhalers
出版日期: 2015年06月02日 內容資訊: 英文 48 Pages
簡介

關於本報告提供品牌學名吸入藥的盈利評估、歐洲與美國的法規環境、吸入器的開發趨勢,及主要品牌學名吸入藥的收益與損失分析等彙整資料。

圖表

摘要整理

簡介

法規環境的檢討

  • 歐洲的法規途徑
  • 美國的法規途徑
  • 法規途徑的摘要
  • 參考文獻

預測、經濟評估

  • 預測方法
  • 美國:Advair的預測
  • EU:Symbicort及 Advair 的預測
  • 收益、損失分析
  • 經濟評估
  • 參考文獻

結論

附錄1

附錄2

參考文獻

圖表清單

目錄
Product Code: DMKC0140315

This analysis examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic and generic inhaled products. The analysis shows that, in some cases, sufficiently attractive financial gains cannot be expected beyond the first few market entrants, as indicated by the appearance of negative net present values for later entrants. This emphasizes the importance of developers paying close attention to, and making frank assessments of, their ability to reach the market ahead of their competitors.

This report addresses the following questions:

  • What are the regulatory requirements for approval of generic inhaled products in Europe and the US?
  • What market share can manufacturers of generic inhaled products expect to achieve depending on their order of market entry?
  • Which branded inhaled products should generic manufacturers target in order to achieve commercial success
  • What factors should generic inhaled product manufacturers assess when deciding on the economic viability of a new product?

An absence of head-to-head trials, along with biosimilar launches, provide payers with leverage to demand favorable pricing for branded products in exchange for formulary access.

This report addresses the following questions:

  • What access controls are payers imposing on interleukins in psoriatic arthritis?
  • What discounts and market access levers will be required to drive uptake of interleukins and second-generation TNFalpha inhibitors?
  • How do US and European payers view the launch of oral small molecules in psoriatic arthritis?
  • What impact will biosimilar entry have on pricing and reimbursement of branded biologics?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

INTRODUCTION

  • 1. Bibliography

REGULATORY LANDSCAPE REVIEW

  • 2. Regulatory pathway in Europe
  • 3. Regulatory pathway in the US
  • 4. Regulatory pathway summary
  • 5. Bibliography

FORECASTING AND ECONOMIC ASSESSMENT

  • 6. Forecasting approach
  • 7. US: Advair forecast
  • 8. EU: Symbicort and Advair forecast
  • 9. Profit and loss analysis
  • 10. Economic appraisal
  • 11. Bibliography

CONCLUSION

APPENDIX 1

APPENDIX 2

BIOGRAPHIES

Back to Top